The authors speculate that the upregulation of STAT3 may mediate the anti-tumor effects of dual HDAC/EGFR inhibition through a tumor-suppressive role, as opposed to its dual action as an oncoprotein [93, 94]. The gene discussed is STAT3; the disease is neoplasm.